[Skip to Navigation]
Sign In
Sep 2012

Two in One: Report of a Patient With Spinocerebellar Ataxia Types 2 and 10

Author Affiliations

Author Affiliations: Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University, Chicago, Illinois.

Arch Neurol. 2012;69(9):1200-1203. doi:10.1001/archneurol.2011.3044

The spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal dominant neurodegenerative diseases characterized by progressive cerebellar ataxia and different genetic mutations. The presence of more than 1 SCA mutation within a single individual is rare. SCA8 mutations coexisting with SCA1, SCA3, or SCA6 mutations have been described in several individuals.1-3SCA3 and SCA17 mutations co-occurred in 2 individuals from the same kindred4; these individuals, however, were asymptomatic and had intermediate-range CAG/CAA expansions in the SCA17 TATA-binding protein gene. Herein, we report a symptomatic patient who carries mutations in both the SCA2 and SCA10 genes, a combination, to our knowledge, that has not been previously reported.

Report of a case

His history was significant for ataxia in multiple family members including his sister, mother, and maternal grandmother (Figure 1). His maternal ancestry was of Mexican, American Indian (Yaqui tribe), and French descent. His sister reported a 20-year history of slowly progressive gait and limb ataxia (onset age, 34 years), along with dysarthria and mild cognitive impairment. His mother developed gait and limb ataxia at about age 60 years and required a wheelchair after about 10 years of disease. Both affected family members reported muscle spasms, dysphagia, and urinary incontinence; neither has had documented seizures, although his sister has been treated with carbamazepine for episodes of bilateral leg stiffening. The patient's paternal ancestry was also of Mexican and French descent; however, there is no known history of ataxia or neurologic disease in his father or paternal relatives. All of these relatives lived far from the patient and were unavailable for direct examination.

Figure 1. Family pedigree. Squares indicate men; circles, women; diagonal lines, deceased. An arrow indicates the index case. Symptoms include ataxia (cases II.4, III.6, IV.2, and IV.3); dysarthria, dysphagia, and muscle cramps (cases III.6, IV.2, and IV.3); paresthesias and possible seizures (case IV.2); and cognitive impairment (case IV.3).

Figure 1. Family pedigree. Squares indicate men; circles, women; diagonal lines, deceased. An arrow indicates the index case. Symptoms include ataxia (cases II.4, III.6, IV.2, and IV.3); dysarthria, dysphagia, and muscle cramps (cases III.6, IV.2, and IV.3); paresthesias and possible seizures (case IV.2); and cognitive impairment (case IV.3).

Figure 2. Brain magnetic resonance imaging. T1-weighted sagittal image demonstrating cerebellar and brainstem atrophy in our patient.

Figure 2. Brain magnetic resonance imaging. T1-weighted sagittal image demonstrating cerebellar and brainstem atrophy in our patient.


Both SCA2 and SCA10 are dominantly inherited SCAs but result from different genetic mutations. The SCA2 mutation is due to an expanded CAG trinucleotide repeat in the gene coding for the cytoplasmic protein ataxin-2 on chromosome 12q24.6 Affected SCA2 individuals have 32 or more CAG repeats, with 37 to 39 repeats representing the most frequent pathologic expansion.6,7 Normal alleles range from 15 to 31 CAG repeats (most commonly 22 repeats) and may have CAA interruptions.6-9 Anticipation may occur, particularly with paternal transmission; those affected individuals generally have longer CAG repeat lengths and earlier symptom onset age.7,9,10 Mean age at onset is typically in the fourth decade. SCA2 has been reported in various ethnicities including Cuban, Indian, Italian, Mexican, South African, and Spanish.11 Besides ataxia, SCA2 features may include slowed saccades (which may progress to ophthalmoparesis), brisk deep tendon reflexes (which may progress to areflexia), peripheral neuropathy, dementia, myoclonus, dystonia, chorea, and levodopa-responsive parkinsonism. Milder phenotypes with less prominent ataxia, neuropathy, dystonia, and myoclonus but greater parkinsonian features have been associated with shorter CAG repeat expansions.8,12

SCA10 maps to chromosome 22q13 and is caused by an unstable pentanucleotide repeat expansion ATTCT in intron 9 of the SCA10 gene, ataxin-10.13,14 Affected SCA10 individuals have 800 to 4500 ATTCT repeats; normal alleles range from 10 to 29 repeats.15 Penetrance is usually complete, although reduced penetrance has been reported in individuals with 360 to 370 repeats.16 Greater instability of repeat expansion occurs with paternal transmission; in SCA10, however, unstable repeat lengths may lead to either intergenerational expansion or contraction.17,18 Anticipation has been observed with contraction of ATTCT repeats,17 thereby suggesting a more complex genotype-phenotype relationship between repeat length and onset age. Symptoms typically begin around ages 10 to 40 years. Besides ataxia, epilepsy (generalized or complex partial seizures), mild cognitive impairment, and abnormal eye movements (eg, ocular dysmetria, fragmented pursuit, and gaze-evoked nystagmus) may occur.15,18-20SCA10 has been described predominantly in Mexican and Brazilian kindreds15,19,20 but also in Argentinean and Venezuelan families.21,22 Common American Indian ancestry has been hypothesized to play a role in the origins of SCA10 in Mexican and South American families.23 Interestingly, our patient has both Mexican and American Indian heritage. The SCA10 phenotype, however, differs in Mexican and South American populations.15,19,21,22 Epilepsy is notable in Mexican kindreds, and some patients have hematologic or hepatic dysfunction. Brazilian patients, however, do not have seizures and lack prominent extracerebellar involvement (ie, neuropathy, cognitive dysfunction, or systemic disease); epilepsy was found in only 3.75% of the Brazilian SCA10 cases, in contrast to up to 60% of SCA10 patients from other geographic regions.24 Dystonia and parkinsonism were reported in the Argentinean family, and peripheral neuropathy has been noted primarily in Mexican patients.24

Our patient has a combination of genetic mutations for 2 different SCAs, types 2 and 10, a combination that, to our knowledge, has not been previously reported. His phenotype includes features common to both SCAs, namely cerebellar ataxia, dysarthria, sensory polyneuropathy, and mild cognitive dysfunction, but also elements specifically associated with the 2 distinct SCA syndromes. His muscle spasms, cramps, and hyporeflexia are more typical for SCA2, whereas his Mexican heritage and possible seizures are more frequently associated with SCA10. While his repeat expansions for both SCAs fall within the pathological ranges, the expansions are mild, a feature that may explain some aspects of his presentation. Whereas prominent slow saccades, highly characteristic of SCA2, were not evident in our patient, prior studies demonstrate that saccadic velocity deficits correlate with repeat length.8,25 As such, his very mildly slowed saccades may reflect the smaller SCA2 repeat expansions (ie, 38 alleles). Alternatively, his SCA10 mutation may have influenced the phenotypic expression of the saccadic deficits. Overall, our patient exhibits a unique clinical phenotype not explained by either SCA2 or SCA10 alone.

By using distinct clinical features (eg, cerebellar syndromes with or without parkinsonism, retinopathy, or dementia), the clinician may consider testing for specific SCAs, although in many cases, there is phenotypic overlap. In our case, we tested for both SCA types because of his overlapping clinical features and ancestral background. Our patient, along with the few other combined SCA case reports,1-4 demonstrates that patients who harbor shared SCA phenotypes could actually carry 2 different SCA mutations. With the growing availability of commercial genetic testing panels, it is important to raise the clinician's awareness of this possibility and not to stop the evaluation with 1 positive test result in cases of atypical presentation.

This patient and his family also may provide unique opportunities to study the interactions of 2 genetic mutations and their effect on clinical expression of disease. Though the clinical and genetic effects of combined SCA mutations are unknown, it has been postulated that SCA8 may modify the effect of polyglutamine transcripts in SCA6 patients.1 Whether SCA10 similarly modifies SCA2, or vice versa, remains to be seen. Furthermore, finding 2 genetic mutations in a patient may have important implications regarding counseling on genetic risk, genetic testing, and disease prognosis.

Back to top
Article Information

Correspondence: Jennifer G. Goldman, MD, MS, Section of Parkinson Disease and Movement Disorders, Department of Neurological Sciences, Rush University Medical Center, 1725 W Harrison St, Ste 755, Chicago, IL 60612 (jennifer_g_goldman@rush.edu).

Accepted for Publication: November 2, 2011.

Published Online: May 21, 2012. doi:10.1001/archneurol.2011.3044

Author Contributions:Study concept and design: Goldman. Acquisition of data: Kapur and Goldman. Analysis and interpretation of data: Goldman. Drafting of the manuscript: Kapur and Goldman. Critical revision of the manuscript for important intellectual content: Goldman. Study supervision: Goldman.

Financial Disclosure: None reported.

Izumi Y, Maruyama H, Oda M,  et al.  SCA8 repeat expansion: large CTA/CTG repeat alleles are more common in ataxic patients, including those with SCA6.  Am J Hum Genet. 2003;72(3):704-70912545428PubMedGoogle ScholarCrossref
Paganoni S, Seelaus CA, Ormond KE, Opal P. Association of spinocerebellar ataxia type 3 and spinocerebellar ataxia type 8 microsatellite expansions: genetic counseling implications.  Mov Disord. 2008;23(1):154-15517987652PubMedGoogle Scholar
Sulek A, Hoffman-Zacharska D, Zdzienicka E, Zaremba J. SCA8 repeat expansion coexists with SCA1—not only with SCA6.  Am J Hum Genet. 2003;73(4):972-97414508711PubMedGoogle Scholar
Xu Q, Li Q, Wang J,  et al.  A spinocerebellar ataxia family with expanded alleles in the TATA-binding protein gene and ataxin-3 gene.  Int J Neurosci. 2010;120(2):159-16120199210PubMedGoogle Scholar
Trouillas P, Takayanagi T, Hallett M,  et al; The Ataxia Neuropharmacology Committee of the World Federation of Neurology.  International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome.  J Neurol Sci. 1997;145(2):205-2119094050PubMedGoogle Scholar
Pulst SM, Nechiporuk A, Nechiporuk T,  et al.  Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.  Nat Genet. 1996;14(3):269-2768896555PubMedGoogle Scholar
Riess O, Laccone FA, Gispert S,  et al.  SCA2 trinucleotide expansion in German SCA patients.  Neurogenetics. 1997;1(1):59-6410735276PubMedGoogle Scholar
Cancel G, Dürr A, Didierjean O,  et al.  Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families.  Hum Mol Genet. 1997;6(5):709-7159158145PubMedGoogle Scholar
Sanpei K, Takano H, Igarashi S,  et al.  Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT.  Nat Genet. 1996;14(3):277-2848896556PubMedGoogle Scholar
Almaguer-Mederos LE, Falcón NS, Almira YR,  et al.  Estimation of the age at onset in spinocerebellar ataxia type 2 Cuban patients by survival analysis.  Clin Genet. 2010;78(2):169-17420095980PubMedGoogle Scholar
Pulst SM. Spinocerebellar ataxia type 2. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, eds. SourceGeneReviews. Seattle: University of Washington; 1993-1998. Updated October 5, 2010
Lu CS, Wu Chou YH, Kuo PC, Chang HC, Weng YH. The parkinsonian phenotype of spinocerebellar ataxia type 2.  Arch Neurol. 2004;61(1):35-3814732617PubMedGoogle Scholar
Zu L, Figueroa KP, Grewal R, Pulst SM. Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22.  Am J Hum Genet. 1999;64(2):594-5999973298PubMedGoogle Scholar
Grewal RP, Tayag E, Figueroa KP,  et al.  Clinical and genetic analysis of a distinct autosomal dominant spinocerebellar ataxia.  Neurology. 1998;51(5):1423-14269818872PubMedGoogle Scholar
Rasmussen A, Matsuura T, Ruano L,  et al.  Clinical and genetic analysis of four Mexican families with spinocerebellar ataxia type 10.  Ann Neurol. 2001;50(2):234-23911506407PubMedGoogle Scholar
Alonso I, Jardim LB, Artigalas O,  et al.  Reduced penetrance of intermediate size alleles in spinocerebellar ataxia type 10.  Neurology. 2006;66(10):1602-160416717236PubMedGoogle Scholar
Matsuura T, Fang P, Lin X,  et al.  Somatic and germline instability of the ATTCT repeat in spinocerebellar ataxia type 10.  Am J Hum Genet. 2004;74(6):1216-122415127363PubMedGoogle Scholar
Grewal RP, Achari M, Matsuura T,  et al.  Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10.  Arch Neurol. 2002;59(8):1285-129012164725PubMedGoogle Scholar
Teive HA, Roa BB, Raskin S,  et al.  Clinical phenotype of Brazilian families with spinocerebellar ataxia 10.  Neurology. 2004;63(8):1509-151215505178PubMedGoogle Scholar
Teive HA, Munhoz RP, Arruda WO, Raskin S, Werneck LC, Ashizawa T. Spinocerebellar ataxia type 10: a review.  Parkinsonism Relat Disord. 2011;17(9):655-66121531163PubMedGoogle Scholar
Gatto EM, Gao R, White MC,  et al.  Ethnic origin and extrapyramidal signs in an Argentinean spinocerebellar ataxia type 10 family.  Neurology. 2007;69(2):216-21817620556PubMedGoogle Scholar
Gallardo M, Soto A. Clinical characterization of a Venezuelan family with spinocerebellar ataxia type 10.  Mov Disord. 2009;24:(suppl 1)  S12Google Scholar
Almeida T, Alonso I, Martins S,  et al.  Ancestral origin of the ATTCT repeat expansion in spinocerebellar ataxia type 10 (SCA10).  PLoS One. 2009;4(2):e455319234597PubMedGoogle Scholar
Teive HA, Munhoz RP, Raskin S,  et al.  Spinocerebellar ataxia type 10: frequency of epilepsy in a large sample of Brazilian patients.  Mov Disord. 2010;25(16):2875-287820818609PubMedGoogle Scholar
Seifried C, Velázquez-Pérez L, Santos-Falcón N,  et al.  Saccade velocity as a surrogate disease marker in spinocerebellar ataxia type 2.  Ann N Y Acad Sci. 2005;1039:524-52715827014PubMedGoogle Scholar